Pfizer's Eliquis, a blood thinner and one of its best-selling therapies, will lose patent exclusivity within the next few years. In the meantime, the company's performance leaves a lot to be desired.

Progressing on a decade-long path to a global travel management program, pharmaceutical company Pfizer this year completed a 24-country agency consolidation in Europe, the Middle East and Africa.

I reaffirm my Buy rating on Pfizer due to expected promising updates on danuglipron and strong capital efficiency metrics, despite the recent stock pullback. Pfizer's management is expected to ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. HUNTSVILLE, Ala. – Operation Warp Speed has ...

Pfizer has reached a transition point as sales of its top products decline. But the company is completing its biggest string of new product launches, a move to spur a new phase of growth. Now, though, ...

Pfizer’s stock rebounded from April lows yet still trades as if COVID and patent cliffs equal business ruin, despite resilient non‑COVID franchises and pipeline optionality. Q3 looked weak, with ...

HUNTSVILLE, Ala. – Operation Warp Speed has announced COVID-19 vaccines may begin being distributed as early as this month. When that happens, Star Market Pharmacy in Huntsville will be ready for one ...